ReviewPharmaceuticals (Basel, Switzerland)2015
γδ T Cell Immunotherapy-A Review.
Review in Pharmaceuticals (Basel, Switzerland), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 54 citations in OpenAlex.
- Immunological Interactions Between Gammadelta T Cells and West Nile Virus in the Infected Host.Reviews in medical virology · 2026Review
- Peptide hydrogel boosts the cytotoxic and metabolic fitness of Vγ9Vδ2 T cells in melanoma immunotherapy.Frontiers in immunology · 2026Article
- Function and Spatial Organization of Tumor-Invasive Human γδ T Cells-What Do We Know?European journal of immunology · 2025Review
- Invariant γδTCR natural killer-like effector T cells in the naked mole-rat.Nature communications · 2024Article
- Human Vγ9Vδ2 T cell expansion and their cytotoxic responses against cholangiocarcinoma.Scientific reports · 2024Article
- The therapeutic role of γδT cells in TNBC.Frontiers in immunology · 2024Review
- γδ T cells mediate robust anti-HIV functions during antiretroviral therapy regardless of immune checkpoint expression.Clinical & translational immunology · 2024Article
- Adenosine 2A receptor contributes to the facilitation of post-infectious irritable bowel syndrome by γδ T cellsWorld journal of gastroenterology · 2023Article
- γδ T cells in immunotherapies for B-cell malignancies.Frontiers in immunology · 2023Review
- Positron Emission Tomography Probes for Imaging Cytotoxic Immune Cells.Pharmaceutics · 2022Review
- Skin γδ T Cells and Their Function in Wound Healing.Frontiers in immunology · 2022Review
- Inhibiting the Unconventionals: Importance of Immune Checkpoint Receptors in γδ T, MAIT, and NKT Cells.Cancers · 2021Review
- Observational
- Strategies to Improve the Antitumor Effect of γδ T Cell Immunotherapy for Clinical Application.International journal of molecular sciences · 2021Review
- Dysfunctional BTN3A together with deregulated immune checkpoints and type I/II IFN dictate defective interplay between pDCs and γδ T cells in melanoma patients, which impacts clinical outcomes.Clinical & translational immunology · 2021Article
- Association between αβ and γδ T-cell subsets and clinicopathological characteristics in patients with breast cancer.Oncology letters · 2020Article
- Article
- Electroporation of NKG2D RNA CAR Improves Vγ9Vδ2 T Cell Responses against Human Solid Tumor Xenografts.Molecular therapy oncolytics · 2020Article
- Potent Bidirectional Cross-Talk Between Plasmacytoid Dendritic Cells and γδT Cells Through BTN3A, Type I/II IFNs and Immune Checkpoints.Frontiers in immunology · 2020Article
- Long noncoding RNA TANCR promotes γδ T cells activation by regulating TRAIL expression inCell & bioscience · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer immunotherapy utilizing Vγ9Vδ2 T cells has been developed over the past decade. A large number of clinical trials have been conducted on various types of solid tumors as well as hematological malignancies. Vγ9Vδ2 T cell-based immunotherapy can be classified into two categories based on the methods of activation and expansion of these cells. Although the in vivo expansion of Vγ9Vδ2 T cells by phosphoantigens or nitrogen-containing bisphosphonates (N-bis) has been translated to early-phase clinical trials, in which the safety of the treatment was confirmed, problems such as activation-induced Vγ9Vδ2 T cell anergy and a decrease in the number of peripheral blood Vγ9Vδ2 T cells after infusion of these stimulants have not yet been solved. In addition, it is difficult to ex vivo expand Vγ9Vδ2 T cells from advanced cancer patients with decreased initial numbers of peripheral blood Vγ9Vδ2 T cells. In this article, we review the clinical studies and reports targeting Vγ9Vδ2 T cells and discuss the development and improvement of Vγ9Vδ2 T cell-based cancer immunotherapy.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.